Onconetix (ONCO) Other Non Operating Income (2022 - 2026)
Onconetix (ONCO) posted quarterly Other Non Operating Income of -$16810.0 for Q1 2026, down 213.44% year-over-year from $14817.9 in Q1 2025, and down 267.41% quarter-over-quarter from $10041.0 in Q4 2025.
Onconetix (ONCO) Other Non Operating Income (2022 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Other Non Operating Income for 5 consecutive years, with -$16810.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 213.44% year-over-year to -$16810.0; the TTM figure through Mar 2026 stood at $186571.0 (up 38.33% YoY), while the FY2025 annual figure was $226041.0, up 33.95% from the prior year.
- Other Non Operating Income retreated to -$16810.0 in Q1 2026 per ONCO's latest filing, from $10041.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $686025.0 in Q4 2023 and bottomed at -$490000.0 in Q3 2023.
- Historically, Other Non Operating Income has averaged $21775.0 across 5 years, with a median of $2343.5 in 2022.
- On a YoY basis, Other Non Operating Income climbed as much as 4159.8% in 2023 and fell as far as 16050.52% in 2023.
- Onconetix's Other Non Operating Income stood at -$16898.0 in 2022, then surged by 4159.8% to $686025.0 in 2023, then tumbled by 81.51% to $126852.0 in 2024, then sank by 92.08% to $10041.0 in 2025, then slumped by 267.41% to -$16810.0 in 2026.
- Business Quant data shows ONCO's Other Non Operating Income at -$16810.0 in Q1 2026, $10041.0 in Q4 2025, and $216000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 136,471.00 |
| Mar 31, 2026 | -16,810.00 |
| Dec 31, 2025 | 10,041.00 |
| Sep 30, 2025 | 216,000.00 |
| Jun 30, 2025 | -22,660.00 |
| Mar 31, 2025 | -5,363.00 |
| Dec 31, 2024 | 126,852.00 |
| Sep 30, 2024 | 44,988.00 |
| Jun 30, 2024 | -31,602.00 |
| Mar 31, 2024 | 28,507.00 |
| Dec 31, 2023 | 686,025.00 |
| Sep 30, 2023 | -490,000.00 |
| Jun 30, 2023 | -215,670.00 |
| Mar 31, 2023 | 1,615.00 |
| Dec 31, 2022 | -16,898.00 |
| Sep 30, 2022 | 3,072.00 |
| Jun 30, 2022 | 30,303.00 |